Skip to content

Released Oct 28, 2020, before the open

10-Q filed Oct 29, 2020, 29 days after period end · 0000917520-20-000047

Q3 2020 · 10-Q
Revenue$370.23M−2.3% vs Q3 2019+43.1% vs Q2 2020
Net Income$32.34MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted$0.38N/M vs Q3 2019no prior Q2 2020 on file
Gross Profit$235,421,000−0.4%
Operating Income$57,542,000N/M
Operating Cash Flowderived$69,639,000+8.4%
Free Cash Flowderived$62,912,000+24.2%
Margins · derived
Gross margin63.6%+1.2 pt vs Q3 2019
Operating margin15.5%+21.0 pt vs Q3 2019
Net margin8.7%+16.0 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$370.23M$379.10M$365.85M$278.83M
Net Income$32.34M-$27.61M$13.30M$3.16M
EPS Diluted$0.38-$0.32$0.15$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR